Story perspectives
Johnson & Johnson Halts Rheumatoid Arthritis Drug Development
8/30/2025
39 4
1 of 1
Story summary
- Johnson & Johnson will halt development of its combination drug for rheumatoid arthritis.
- This decision follows a mid-stage trial that revealed no significant advantages over current anti-TNF? therapies.
- Rheumatoid arthritis is an autoimmune condition characterized by joint pain and stiffness.
- The announcement was made on August 28, 2025.
